<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Can the Signal-to-Noise Ratio of Choline in Magnetic Resonance Spectroscopy Reflect the Aggressiveness of Endometrial Cancer?" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/can-the-signal-to-noise-ratio-of-choline-in-magnetic-resonance-spectroscopy-reflect-the-aggressivene/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/can-the-signal-to-noise-ratio-of-choline-in-magnetic-resonance-spectroscopy-reflect-the-aggressivene/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2015-03-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Can the Signal-to-Noise Ratio of Choline in Magnetic Resonance Spectroscopy Reflect the Aggressiveness of Endometrial Cancer?" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T02:43:55+00:00","datePublished":"2015-03-31T17:00:00+00:00","description":"Rationale and Objectives","headline":"Can the Signal-to-Noise Ratio of Choline in Magnetic Resonance Spectroscopy Reflect the Aggressiveness of Endometrial Cancer?","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/can-the-signal-to-noise-ratio-of-choline-in-magnetic-resonance-spectroscopy-reflect-the-aggressivene/"},"url":"https://clinicaltree.github.io/posts/can-the-signal-to-noise-ratio-of-choline-in-magnetic-resonance-spectroscopy-reflect-the-aggressivene/"}</script><title>Can the Signal-to-Noise Ratio of Choline in Magnetic Resonance Spectroscopy Reflect the Aggressiveness of Endometrial Cancer? | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Can the Signal-to-Noise Ratio of Choline in Magnetic Resonance Spectroscopy Reflect the Aggressiveness of Endometrial Cancer?</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Can the Signal-to-Noise Ratio of Choline in Magnetic Resonance Spectroscopy Reflect the Aggressiveness of Endometrial Cancer?</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1427821200" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Mar 31, 2015 </em> </span> <span> Updated <em class="" data-ts="1681094635" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Xue Han MD</a> </em>, <em> <a href="">Jingxia Kang MM</a> </em>, <em> <a href="">Jie Zhang MD</a> </em>, <em> <a href="">Jianjun Xiu MD</a> </em>, <em> <a href="">Zhaoqin Huang MD</a> </em>, <em> <a href="">Chunrun Yang MD</a> </em>, <em> <a href="">Xichao Sun MD</a> </em>, <em> <a href="">Caixia Fu SM</a> </em>, <em> <a href="">Qingwei Liu MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="1937 words"> <em>10 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>To differentiate endometrial cancer (ECa) from benign lesions in endometrial or in submucosa (BLs-ESm), and investigate whether the signal-to-noise ratio (SNR) of choline-containing compounds (Cho) obtained from three-dimensional 1 H magnetic resonance spectroscopy (MRS) is associated with the aggressiveness of ECa.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Thirty-three patients with ECa and 15 patients with BLs-ESm underwent preoperative multivoxel 1 H MRS at 3 T MR. The amplitude of Cho peak of each voxel was recorded, and the corresponding SNR of Cho peak (Cho SNR ) was calculated. The maximum Cho SNR (max Cho SNR ) for each lesion was identified. The max Cho SNR of ECa and BLs-ESm, as well as type I ECa and type II ECa, was compared. The relationship between max Cho SNR and pathologic characteristics of tumors, including tumor grade, stage, type, and tumor size, was analyzed.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The mean max Cho SNR (±standard deviation [SD]) was 30.93 ± 16.89 for ECa and 10.40 ± 3.07 for BLs-ESm ( <em>P</em> &lt; .001). The mean max Cho SNR for type II ECa (48.54 ± 21.46) was higher than that for type I ECa (26.19 ± 12.02, <em>P</em> = .001). There were no significant differences among different grades ( <em>P</em> = .449). The Spearman coefficient between max Cho SNR and stage was 0.423 ( <em>P</em> = .014); the difference existed only between Ia and III ECa ( <em>P</em> = .048). The Pearson coefficient between Cho SNR and tumor size was 0.515 ( <em>P</em> = .002).</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The max Cho SNR obtained from MRS can differentiate ECa from BLs and type I ECa and type II ECa, but cannot differentiate between each grade ECa and each International Federation of Gynecology and Obstetrics stage ECa. However, max Cho SNR increased with the increase in International Federation of Gynecology and Obstetrics stage and size of ECa.</p><p>Endometrial cancer (ECa) is one of the three most common female genital tract malignancies in China. The incidence of ECa is rising worldwide in recent years. Correct diagnosis of ECa and benign lesions in endometrial or in submucosa (BLs-ESm) before surgery is very important to personalize treatment. The ECa type (type I, estrogen dependent; type II, estrogen independent), grade, stage, and tumor size were fundamental biological indicators of aggressiveness and prognosis of ECa . Type II ECa generally contains rare but aggressive subtypes of ECa, that is, squamous cell carcinoma, adenosquamous carcinoma, papillary serous carcinoma, and clear cell carcinoma, which closely related to lymph node metastasis and prognosis. The endometrial sampling is not sensitive enough to be used alone to exclude ECa. As a traditional method of diagnosis of ECa, the fractional dilatation and curettage cannot always exclude ECa when endometrial hyperplasia, especially atypical hyperplasia, was diagnosed because of limited samples . There were 16.7%–62.5% patients with atypical hyperplasia in dilatation and curettage having a diagnosis of ECa in the hysterectomy specimens .</p><p>Magnetic resonance (MR) imaging is considered as the optimal imaging modality in assessing the invasion of uterine cancers . The accuracy of staging ECa using MR imaging was high . MR imaging has also been used in determining the origin of uterine cancer and differentiation of malignant tumors from benign lesions of uterus . As a noninvasive examination, MR spectroscopy (MRS) can provide the tissue biochemical information. The clinical application of MRS has been steadily increasing in recent years. MRS contributes to the diagnosis, differentiation of malignant tumors from benign lesions, and assessing tumor aggressiveness in brain , breast , and prostate . Choline-containing compounds (Cho) increased in actively proliferating tumors . The differentiation of malignant tumors from benign lesions of uterus with single voxel MRS has been reported in a study by Takeuchi et al. . The size of single voxel was often large. The large volume of a voxel may result in the restriction of measurement of small tumor, although a signal-to-noise ratio (SNR) of single voxel MRS was relatively high. However, the differentiation of ECa from BLs-ESm and the assessment of ECa aggressiveness with multivoxel MRS have not been systematically investigated.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patients"><span class="mr-2">Patients</span><a href="#patients" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="mr-imaging"><span class="mr-2">MR Imaging</span><a href="#mr-imaging" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Parameters of Magnetic Resonance Imaging Sequences</p><p>Sequences TR (ms) TE (ms) ST (mm) Average FOV (cm 2 ) Matrix Axial T2W 3110 101 3–4.5 2 20 × 20 320 × 256 Coronal T2W 3350 97 3–4 2 20 × 20 320 × 256 Sagittal T2W 2950 101 3–4 2 20 × 20 320 × 310 MRS ∗ 750 145 — 6 — — DWI † 6200 63 3–4.5 6 20 × 20 160 × 120 T1W-DCE (VIBE) 5.21 1.8 3–4 1 26 × 26 224 × 161</p><p>DCE, dynamic contrast–enhanced imaging; DWI, diffusion-weighted imaging; FOV, field of view; ST, slice thickness; T1W, T1-weighted; T2W, T2-weighted; TE, echo time; TR, repetition time; VIBE, volume interpolated body examination.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="mrs-data-analysis"><span class="mr-2">MRS Data Analysis</span><a href="#mrs-data-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Root−mean−squareerror=(fittingerror)Cho(3.4−3.0)×1024/10−−−−−−−−−−−−√. Root</p><p>-</p><p>mean</p><p>-</p><p>square</p><p>error</p><p>=</p><p>(</p><p>fitting</p><p>error</p><p>)</p><p>Cho</p><p>(</p><p>3.4</p><p>−</p><p>3.0</p><p>)</p><p>×</p><p>1024</p><p>/</p><p>10</p><p>.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>SDnoise=(fittingerror)noise(9.5−7)×1024/10−−−−−−−−−−−√. SD</p><p>noise</p><p>=</p><p>(</p><p>fitting</p><p>error</p><p>)</p><p>noise</p><p>(</p><p>9.5</p><p>−</p><p>7</p><p>)</p><p>×</p><p>1024</p><p>/</p><p>10</p><p>.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="histopathologic-analysis"><span class="mr-2">Histopathologic Analysis</span><a href="#histopathologic-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 2</p><p>The Number of Patients with Different Histopathologic Results</p><p>Lesions Value No. of lesions (no. of voxel) ECa 33 BLs-ESm 15 Type of ECa Type I (estrogen dependent) 26 Type II (estrogen independent) 7 Subtype of type II ECa Adenosquamous 2 Squamous cell 1 Endometrioid 2 Serous 1 Mixed endometrioid/clear cell 1 Histologic grade of ECa G1 9 G2 17 G3 7 FIGO stage of ECa Ia 17 Ib 8 II 2 III 6 No. of BL Polyp 4 Simple hyperplasia 3 Complex hyperplasia with or without atypia 5 Ploypoid adenomyoma 2 Leiomyomas 1</p><p>BLs-ESm, benign lesions in endometrial or in submucosa; ECa, endometrial cancer; FIGO, International Federation of Gynecology and Obstetrics.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/CantheSignaltoNoiseRatioofCholineinMagneticResonanceSpectroscopyReflecttheAggressivenessofEndometrialCancer/0_1s20S1076633214004723.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/CantheSignaltoNoiseRatioofCholineinMagneticResonanceSpectroscopyReflecttheAggressivenessofEndometrialCancer/0_1s20S1076633214004723.jpg" alt="Figure 1, (a) 78Y, endometrial polyp, the RMSE of the Cho peak to amplitude of Cho peak ( A Cho ) was 13.1%, and the signal-to-noise ratio (SNR) of Cho (Cho SNR ) was 10.48. (b) 56Y, endometrial cancer (FIGO Ia and type I), the RMSE of the Cho peak to A Cho was 9.7%, and the Cho SNR was 16.77. (c) 58Y, endometrial cancer (adenosquamous, FIGO IIIc and type II), the RMSE of the Cho peak to A Cho was 5.8%, and the Cho SNR was 57.11. Cho, choline-containing compounds; FIGO, International Federation of Gynecology and Obstetrics; RMSE, root-mean-square error." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/CantheSignaltoNoiseRatioofCholineinMagneticResonanceSpectroscopyReflecttheAggressivenessofEndometrialCancer/1_1s20S1076633214004723.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/CantheSignaltoNoiseRatioofCholineinMagneticResonanceSpectroscopyReflecttheAggressivenessofEndometrialCancer/1_1s20S1076633214004723.jpg" alt="Figure 2, (a) Box plot of max Cho SNR obtained in endometrial cancer (ECa) and benign lesions in endometrial or submucosa (BLs-ESm). The max Cho SNR in ECa was significantly higher than that in BLs-ESm. (b) The ROC curve to differentiate ECa from BLs-ESm. The area under the ROC curve was 0.903. Cho, choline-containing compounds; ROC, receiver operating characteristic; SNR, signal-to-noise ratio." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/CantheSignaltoNoiseRatioofCholineinMagneticResonanceSpectroscopyReflecttheAggressivenessofEndometrialCancer/2_1s20S1076633214004723.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/CantheSignaltoNoiseRatioofCholineinMagneticResonanceSpectroscopyReflecttheAggressivenessofEndometrialCancer/2_1s20S1076633214004723.jpg" alt="Figure 3, (a) Box plot of max Cho SNR obtained in type I and type II endometrial cancer (ECa). The Cho/water in type II ECa was significantly higher than that in type I ECa. (b) The ROC curve to differentiate type I ECa from type II ECa. The area under the ROC curve was 0.813. Cho, choline-containing compounds; ROC, receiver operating characteristic; SNR, signal-to-noise ratio." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/CantheSignaltoNoiseRatioofCholineinMagneticResonanceSpectroscopyReflecttheAggressivenessofEndometrialCancer/3_1s20S1076633214004723.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/CantheSignaltoNoiseRatioofCholineinMagneticResonanceSpectroscopyReflecttheAggressivenessofEndometrialCancer/3_1s20S1076633214004723.jpg" alt="Figure 4, (a) There were no significant differences for max Cho SNR among different grades ECa. (b) For different stages ECa, the difference existed only between Ia and III ECa, but there was a tendency for max Cho SNR to increase with an increase in tumor stage. (c) There was a positive correlation between max Cho SNR and tumor size. Cho, choline-containing compounds; FIGO, International Federation of Gynecology and Obstetrics; SNR, signal-to-noise ratio." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="conclusions-1"><span class="mr-2">Conclusions</span><a href="#conclusions-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Nofech-Mozes S., Ghorab Z., Ismiil N., et. al.: Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases. Am J Clin Pathol 2008; 129: pp. 110-114.</p><li><p>2. Zhu H.L., Liang X.D., Wang J.L., et. al.: Hysteroscopy and directed biopsy in the diagnosis of endometrial carcinoma. Chin Med J 2010; 123: pp. 3524-3528.</p><li><p>3. Eddib A., Allaf B., Lee J., et. al.: Risk for advanced-stage endometrial cancer in surgical specimens from patients with complex endometrial hyperplasia with atypia. Gynecol Obstet Invest 2012; 73: pp. 38-42.</p><li><p>4. Karamursel B.S., Guven S., Tulunay G., et. al.: Which surgical procedure for patients with atypical endometrial hyperplasia?. Int J Gynecol Cancer 2005; 15: pp. 127-131.</p><li><p>5. Trimble C.L., Kauderer J., Zaino R., et. al.: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106: pp. 812-819.</p><li><p>6. Harry V.N., Deans H., Ramage E., et. al.: Magnetic resonance imaging in gynecological oncology. Int J Gynecol Cancer 2009; 19: pp. 186-193.</p><li><p>7. Djurdjevic S., Zivaljevic M., Semnic R., et. al.: Diagnostic significance of ultrasound and magnetic resonance imaging scan in the presurgical determination of FIGO stage of endometrial cancer. J BUON 2010; 15: pp. 382-388.</p><li><p>8. Haldorsen I.S., Salvesen H.B.: Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques. Clin Radiol 2012; 67: pp. 2-12.</p><li><p>9. Vargas H.A., Akin O., Zheng J., et. al.: The value of MR imaging when the site of uterine cancer origin is uncertain. Radiology 2011; 258: pp. 785-792.</p><li><p>10. Thomassin-Naggara I., Dechoux S., Bonneau C., et. al.: How to differentiate benign from malignant myometrial tumours using MR imaging. Eur Radiol 2013; 23: pp. 2306-2314.</p><li><p>11. Sibtain N.A., Howe F.A., Saunders D.E.: The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol 2007; 62: pp. 109-119.</p><li><p>12. Gao F., Edden R.A., Li M., et. al.: Edited magnetic resonance spectroscopy detects an age-related decline in brain GABA levels. Neuroimage 2013; 78: pp. 75-82.</p><li><p>13. Bartella L., Thakur S.B., Morris E.A., et. al.: Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology 2007; 245: pp. 80-87.</p><li><p>14. Kobus T., Vos P.C., Hambrock T., et. al.: Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. Radiology 2012; 265: pp. 457-467.</p><li><p>15. Zhang J., Jing H., Han X., et. al.: Diffusion-weighted imaging of prostate cancer on 3T MR: relationship between apparent diffusion coefficient values and Ki-67 expression. Acad Radiol 2013; 20: pp. 1535-1541.</p><li><p>16. Payne G.S., Schmidt M., Morgan V.A., et. al.: Evaluation of magnetic resonance diffusion and spectroscopy measurements as predictive biomarkers in stage 1 cervical cancer. Gynecol Oncol 2010; 116: pp. 246-252.</p><li><p>17. Takeuchi M., Matsuzaki K., Harada M.: Differentiation of benign and malignant uterine corpus tumors by using proton MR spectroscopy at 3T: preliminary study. Eur Radiol 2011; 21: pp. 850-856.</p><li><p>18. Celik O., Hascalik S., Sarac K., et. al.: Magnetic resonance spectroscopy of premalignant and malignant endometrial disorders: a feasibility of in vivo study. Eur J Obstet Gynecol Reprod Biol 2005; 118: pp. 241-245.</p><li><p>19. Okada T., Harada M., Matsuzaki K., et. al.: Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy. J Magn Reson Imaging 2001; 13: pp. 912-917.</p><li><p>20. Mahon M.M., Cox I.J., Dina R., et. al.: (1)H magnetic resonance spectroscopy of preinvasive and invasive cervical cancer: in vivo-ex vivo profiles and effect of tumor load. J Magn Reson Imaging 2004; 19: pp. 356-364.</p><li><p>21. Booth S.J., Pickles M.D., Turnbull L.W.: In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla. BJOG 2009; 116: pp. 300-303.</p><li><p>22. Glunde K., Bhujwalla Z.M., Ronen S.M.: Choline metabolism in malignant transformation. Nat Rev Cancer 2011; 11: pp. 835-848.</p><li><p>23. Danishad K.K., Sharma U., Sah R.G., et. al.: Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed 2010; 23: pp. 233-241.</p><li><p>24. McLean M.A., Priest A.N., Joubert I., et. al.: Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T. Magn Reson Med 2009; 62: pp. 855-861.</p><li><p>25. Baik H.M., Su M.Y., Yu H., et. al.: Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T. Magma (New York, NY) 2006; 19: pp. 96-104.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-22/'>Volume 22</a>, <a href='/categories/issue-4/'>Issue 4</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Can%20the%20Signal-to-Noise%20Ratio%20of%20Choline%20in%20Magnetic%20Resonance%20Spectroscopy%20Reflect%20the%20Aggressiveness%20of%20Endometrial%20Cancer?%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fcan-the-signal-to-noise-ratio-of-choline-in-magnetic-resonance-spectroscopy-reflect-the-aggressivene%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Can%20the%20Signal-to-Noise%20Ratio%20of%20Choline%20in%20Magnetic%20Resonance%20Spectroscopy%20Reflect%20the%20Aggressiveness%20of%20Endometrial%20Cancer?%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fcan-the-signal-to-noise-ratio-of-choline-in-magnetic-resonance-spectroscopy-reflect-the-aggressivene%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fcan-the-signal-to-noise-ratio-of-choline-in-magnetic-resonance-spectroscopy-reflect-the-aggressivene%2F&text=Can%20the%20Signal-to-Noise%20Ratio%20of%20Choline%20in%20Magnetic%20Resonance%20Spectroscopy%20Reflect%20the%20Aggressiveness%20of%20Endometrial%20Cancer?%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/acute-stroke-imaging/"><div class="card-body"> <em class="small" data-ts="1427821200" data-df="ll" > Mar 31, 2015 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Acute Stroke Imaging</h3><div class="text-muted small"><p> Rationale and Objectives Magnetic resonance (MR) imaging (MRI) provides information that can be used to estimate the symptom onset in patients with wake-up stroke (WUS). Time-resolved MR angiograp...</p></div></div></a></div><div class="card"> <a href="/posts/assessment-of-liver-function-and-liver-fibrosis-with-dynamic-gd-eob-dtpa-enhanced-mri/"><div class="card-body"> <em class="small" data-ts="1427821200" data-df="ll" > Mar 31, 2015 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Assessment of Liver Function and Liver Fibrosis with Dynamic Gd-EOB-DTPA–Enhanced MRI</h3><div class="text-muted small"><p> Rationale and Objectives To evaluate the ability of segmental linear fitting analysis of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid liver perfusion magnetic resonance imaging (MRI...</p></div></div></a></div><div class="card"> <a href="/posts/change-overload-and-the-program-director/"><div class="card-body"> <em class="small" data-ts="1427821200" data-df="ll" > Mar 31, 2015 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Change Overload and the Program Director</h3><div class="text-muted small"><p> An epidemic has swept across radiology. Its principal victims are radiology residency and fellowship program directors. Its symptoms are often vague and nonspecific but include fatigue, disorientat...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/assessment-of-liver-function-and-liver-fibrosis-with-dynamic-gd-eob-dtpa-enhanced-mri/" class="btn btn-outline-primary" prompt="Older"><p>Assessment of Liver Function and Liver Fibrosis with Dynamic Gd-EOB-DTPA–Enhanced MRI</p></a> <a href="/posts/change-overload-and-the-program-director/" class="btn btn-outline-primary" prompt="Newer"><p>Change Overload and the Program Director</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
